Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.78 |
| ▸ | MEN1 | O00255 | 8/20 | 0.78 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10960859 | 0.88 | KMT2A (1.00) | KMT2AMEN1RAB9AMAPTNPC1 | |
| SCHEMBL5455550 | 0.83 | KMT2A (0.65) | KMT2AMEN1RAB9AMAPTNPC1 | |
| SCHEMBL5453211 | 0.82 | ALDH1A1 (0.72) | KMT2AMEN1MITFRAB9AMAPT | |
| SCHEMBL13956732 | 0.81 | ALDH1A1 (0.57) | KMT2AMEN1MITFRAB9AMAPT | |
| SCHEMBL12012121 | 0.80 | ALDH1A1 (0.75) | KMT2AMEN1RAB9AMAPTNPC1 | |
| SCHEMBL3054964 | 0.80 | ALDH1A1 (0.66) | KMT2AMEN1MITFRAB9AMAPT | |
| SCHEMBL5443694 | 0.80 | MITF (0.63) | KMT2AMEN1MITFRAB9AMAPT | |
| SCHEMBL1514749 | 0.78 | RAB9A (0.65) | KMT2AMEN1MITFRAB9AMAPT | |
| Etocarlide SCHEMBL7873047 | 0.77 | KMT2A (0.73) | KMT2AMEN1RAB9AMAPTNPC1 | |
| SCHEMBL14096622 | 0.76 | ALDH1A1 (0.69) | KMT2AMEN1RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101129295-B | There is the binary initiator system of good storage stability and especially suitable for acidic system | HERAEUS KULZER GMBH (DE) | 2016-02-10 | — | — | CN | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| CN-101129295-A | 2-component initiator system (amine free) with storage stability and especially suitable for acidic systems | HERAEUS KULZER GMBH (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | KMT2A 4579/4885MEN1 4577/4885MITF 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.